{"id":66487,"date":"2026-05-27T21:19:12","date_gmt":"2026-05-27T13:19:12","guid":{"rendered":"https:\/\/flcube.com\/?p=66487"},"modified":"2026-05-27T21:19:13","modified_gmt":"2026-05-27T13:19:13","slug":"fosun-pharma-invests-rmb-220-million-in-hepa-thera-becomes-second-largest-shareholder-in-liver-disease-biotech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66487","title":{"rendered":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced its participation in a <strong>Series B financing round<\/strong> for <strong>Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd.<\/strong> (Hepa Thera), contributing <strong>RMB 220 million<\/strong> (USD 32.4 million). Following the transaction, Fosun Pharma will hold <strong>20.8709%<\/strong> of Hepa Thera, becoming the liver disease specialist&#8217;s <strong>second largest shareholder<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-investment-overview\" class=\"wp-block-heading\">Investment Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Investor<\/strong><\/td><td>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196)<\/td><\/tr><tr><td><strong>Portfolio Company<\/strong><\/td><td>Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera)<\/td><\/tr><tr><td><strong>Investment Amount<\/strong><\/td><td>RMB 220 million (USD 32.4 million)<\/td><\/tr><tr><td><strong>Post-Investment Stake<\/strong><\/td><td>20.8709%<\/td><\/tr><tr><td><strong>Investor Position<\/strong><\/td><td>Second largest shareholder<\/td><\/tr><tr><td><strong>Incubation Relationship<\/strong><\/td><td>Hepa Thera incubated through Fosun Health Capital New Drug Fund<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-hepa-thera-pipeline-portfolio\" class=\"wp-block-heading\">Hepa Thera Pipeline Portfolio<\/h2>\n\n\n\n<h3 id=\"h-ht-101-sirna-therapeutic-for-chronic-hepatitis-b\" class=\"wp-block-heading\">HT-101 \u2013 siRNA Therapeutic for Chronic Hepatitis B<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> GalNAc-conjugated siRNA innovative drug<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> High liver targeting specificity<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Silences HBV mRNA to block synthesis of multiple viral proteins at source<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase II clinical trials in China for chronic hepatitis B virus (cHBV) infection<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Addresses root cause of viral replication rather than downstream effects<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-ht-102-neutralizing-antibody-for-chronic-hepatitis-b\" class=\"wp-block-heading\">HT-102 \u2013 Neutralizing Antibody for Chronic Hepatitis B<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Fully human monoclonal antibody<\/li>\n\n\n\n<li><strong>Target:<\/strong> HBsAg (hepatitis B surface antigen)<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n\n\n\n<li>Prevents HBV reinfection<\/li>\n\n\n\n<li>Clears HBsAg-containing subviral particles from circulation<\/li>\n\n\n\n<li>Reduces subviral particle-mediated immunosuppression<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Phase II studies in cHBV in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-combination-therapy-strategy\" class=\"wp-block-heading\">Combination Therapy Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rationale:<\/strong> Dual targeting of HBsAg in both <strong>hepatocytes<\/strong> (HT-101) and <strong>peripheral blood<\/strong> (HT-102)<\/li>\n\n\n\n<li><strong>Mechanistic Synergy:<\/strong> Complementary mechanisms addressing different aspects of HBV lifecycle<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> Combination regimen being evaluated in Phase II cHBV study in China<\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Functional cure of chronic hepatitis B through comprehensive viral suppression and immune restoration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-context\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<h3 id=\"h-fosun-pharma-investment-thesis\" class=\"wp-block-heading\">Fosun Pharma Investment Thesis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vertical Integration:<\/strong> Strengthens Fosun&#8217;s position in hepatology therapeutics<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Adds innovative modalities (siRNA + monoclonal antibody) to existing pipeline<\/li>\n\n\n\n<li><strong>Incubation Success:<\/strong> Validates Fosun Health Capital New Drug Fund&#8217;s biotech development model<\/li>\n\n\n\n<li><strong>Commercial Optionality:<\/strong> Potential future acquisition or partnership rights<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hepatitis-b-market-opportunity\" class=\"wp-block-heading\">Hepatitis B Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Burden:<\/strong> 296 million people chronically infected with HBV worldwide<\/li>\n\n\n\n<li><strong>China Prevalence:<\/strong> Approximately 70 million chronic HBV carriers<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Current therapies rarely achieve functional cure; significant unmet need for novel approaches<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> $5+ billion global HBV therapeutics market projected to grow with curative therapies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Leadership:<\/strong> Combination of siRNA and neutralizing antibody represents cutting-edge approach<\/li>\n\n\n\n<li><strong>GalNAc Technology:<\/strong> Leverages proven liver-targeting platform for enhanced efficacy and reduced systemic exposure<\/li>\n\n\n\n<li><strong>Functional Cure Focus:<\/strong> Aligns with industry shift toward curative rather than suppressive HBV therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Status:<\/strong> Both HT-101 and HT-102 in Phase II monotherapy and combination studies<\/li>\n\n\n\n<li><strong>Data Readouts:<\/strong> Expected 2027-2028 timeframe<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential breakthrough therapy designation given novel mechanism and high unmet need<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Global development possible following Chinese clinical validation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding investment outcomes, clinical development timelines, and market expectations for Hepa Thera&#8217;s pipeline. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600196_20260527_CY30.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260527_CY30.\"><\/object><a id=\"wp-block-file--media-4ba12e28-d040-406a-9a9f-17df12b9fb7b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600196_20260527_CY30.pdf\">600196_20260527_CY30<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/600196_20260527_CY30.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4ba12e28-d040-406a-9a9f-17df12b9fb7b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,159,893,64,892,89,4758],"class_list":["post-66487","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-fosun-pharmaceutical","tag-hkg-2196","tag-rnai-aso","tag-sha-600196","tag-viral-hepatitis","tag-xingyao-kunze-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist&#039;s second largest shareholder.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66487\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist&#039;s second largest shareholder.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66487\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T13:19:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T13:19:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech\",\"datePublished\":\"2026-05-27T13:19:12+00:00\",\"dateModified\":\"2026-05-27T13:19:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"RNAi \\\/ ASO\",\"SHA: 600196\",\"Viral hepatitis\",\"Xingyao Kunze Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66487#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66487\",\"name\":\"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T13:19:12+00:00\",\"dateModified\":\"2026-05-27T13:19:13+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist's second largest shareholder.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66487\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66487#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist's second largest shareholder.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66487","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist's second largest shareholder.","og_url":"https:\/\/flcube.com\/?p=66487","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T13:19:12+00:00","article_modified_time":"2026-05-27T13:19:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66487#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66487"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech","datePublished":"2026-05-27T13:19:12+00:00","dateModified":"2026-05-27T13:19:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66487"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Fosun Pharmaceutical","HKG: 2196","RNAi \/ ASO","SHA: 600196","Viral hepatitis","Xingyao Kunze Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66487#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66487","url":"https:\/\/flcube.com\/?p=66487","name":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T13:19:12+00:00","dateModified":"2026-05-27T13:19:13+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a Series B financing round for Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (Hepa Thera), contributing RMB 220 million (USD 32.4 million). Following the transaction, Fosun Pharma will hold 20.8709% of Hepa Thera, becoming the liver disease specialist's second largest shareholder.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66487#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66487"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66487#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66487"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66487\/revisions"}],"predecessor-version":[{"id":66489,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66487\/revisions\/66489"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}